Published in Vaccine Weekly, March 28th, 2001
Leprosy remains a worldwide problem despite vaccination with BCG, and development of new vaccines is imperative, said E. Martin and colleagues at the Centenary Institute for Cancer Medicine and Cell Biology in Washington, DC.
"The immune dominant 35 kDa protein, shared [by] Mycobacterium leprae and M. avium, but not M. tuberculosis or BCG, is recognized by >90% of leprosy patients, making it an ideal...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.